Business Description
Moleculin Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US60855D2009
Description
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.39 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 20.4 | |||||
| 3-Year EPS without NRI Growth Rate | 21.3 | |||||
| 3-Year FCF Growth Rate | 23.6 | |||||
| 3-Year Book Growth Rate | -20.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 26.14 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.23 | |||||
| 9-Day RSI | 41.05 | |||||
| 14-Day RSI | 43.08 | |||||
| 6-1 Month Momentum % | -50.67 | |||||
| 12-1 Month Momentum % | -70.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | |||||
| Quick Ratio | 2.39 | |||||
| Cash Ratio | 1.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -42.5 | |||||
| Shareholder Yield % | -56.71 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -89.39 | |||||
| ROA % | -69.42 | |||||
| ROIC % | -232.41 | |||||
| 3-Year ROIIC % | -10633.33 | |||||
| ROC (Joel Greenblatt) % | -3860.76 | |||||
| ROCE % | -90.69 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.37 | |||||
| Price-to-Tangible-Book | 1 | |||||
| EV-to-EBIT | 0.11 | |||||
| EV-to-EBITDA | 0.11 | |||||
| EV-to-FCF | 0.12 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 2.2 | |||||
| Earnings Yield (Greenblatt) % | 909.09 | |||||
| FCF Yield % | -353.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moleculin Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -11.815 | ||
| Beta | 1.84 | ||
| Volatility % | 71.41 | ||
| 14-Day RSI | 43.08 | ||
| 14-Day ATR ($) | 0.012181 | ||
| 20-Day SMA ($) | 2.45205 | ||
| 12-1 Month Momentum % | -70.32 | ||
| 52-Week Range ($) | 2.2828 - 14.849999 | ||
| Shares Outstanding (Mil) | 2.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moleculin Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moleculin Biotech Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Moleculin Biotech Inc Frequently Asked Questions
What is Moleculin Biotech Inc(LTS:0K2H)'s stock price today?
The current price of LTS:0K2H is $2.44. The 52 week high of LTS:0K2H is $14.85 and 52 week low is $2.28.
When is next earnings date of Moleculin Biotech Inc(LTS:0K2H)?
The next earnings date of Moleculin Biotech Inc(LTS:0K2H) is 2024-11-11.
Does Moleculin Biotech Inc(LTS:0K2H) pay dividends? If so, how much?
Moleculin Biotech Inc(LTS:0K2H) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers